Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2015; 21(20): 6384-6390
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6384
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6384
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection
Sophie Schneitler, Dieter Häussinger, Dirk Graf, Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty, University Düsseldorf, D-40225 Düsseldorf, Germany
Patric Kröpil, Gerald Antoch, Department of Diagnostic and Interventional Radiology, Medical Faculty, University Düsseldorf, D-40225 Düsseldorf, Germany
Wolfram Trudo Knoefel, Department of General Surgery, Medical Faculty, University Düsseldorf, D-40225 Düsseldorf, Germany
Jasmin Riemer, Department of Pathology, Medical Faculty, University Düsseldorf, D-40225 Düsseldorf, Germany
Author contributions: Schneitler S, Graf D, Kröpil P, Riemer J, Antoch G, Knoefel WT and Häussinger D designed the report; Schneitler S, Graf D and Kröpil P wrote the paper; Schneitler S collected the clinical data; all authors provided final approval of the version to be published.
Supported by University of Düsseldorf, Medical Faculty, Düsseldorf, Germany.
Ethics approval: This case report has been reviewed and approved by the Ethics Committee of the School of Medicine of the University of Düsseldorf, Düsseldorf, Germany.
Informed consent: The patients described in this case report provided informed written consent for publication of their data in regards to this study.
Conflict-of-interest: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dirk Graf, PhD, Senior Consultant, Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine-University Düsseldorf, Medical Faculty Düsseldorf, Germany, Moorenstrasse 5, D-40225 Düsseldorf, Germany. dirk.graf@med.uni-duesseldorf.de
Telephone: +49-211- 8108122 Fax: +49-211-8118132
Received: December 8, 2014
Peer-review started: December 9, 2014
First decision: January 8, 2015
Revised: February 7, 2015
Accepted: March 18, 2015
Article in press: March 19, 2015
Published online: May 28, 2015
Processing time: 172 Days and 18.3 Hours
Peer-review started: December 9, 2014
First decision: January 8, 2015
Revised: February 7, 2015
Accepted: March 18, 2015
Article in press: March 19, 2015
Published online: May 28, 2015
Processing time: 172 Days and 18.3 Hours
Core Tip
Core tip: The FOLFIRINOX regimen is a promising treatment option for metastatic pancreatic carcinoma. This case report describes two cases in which treating metastatic pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy prior to R0 resection was possible. The positive outcomes for these patients provide hope that metastatic pancreatic neoplasms may be cured in certain cases.